Unlicensed Medicines Product Categories and Therapeutic Areas
Published On : October 2026
Product categories describe what a medicine is, such as a specialty biologic or a cell therapy, while therapeutic areas describe the disease field it addresses. In access programs the second view often explains more about how supply is organised than the first.
Within the unlicensed medicines and managed access programs market, eight product categories and seven therapeutic areas are tracked, and they overlap because most categories are defined by the disease field in which they are used.
Therapeutic area shapes the patient population, which in turn shapes the access route. A field with very small patient numbers tends to rely on individual named patient requests, while a field with a larger number of eligible patients is more likely to be served by a structured program.
It also shapes the people involved. Oncology programs usually involve cancer centres and specialist oncology pharmacists, whereas rare disease programs often involve a small number of expert centres that see patients from many countries.
Therapeutic area influences the timing of demand. Fields with fast-moving development pipelines produce a steady flow of products that reach one region ahead of others, and each gap between regions creates a period in which access programs are needed.
Handling requirements add a further layer. Some products require frozen or ultra-cold shipment, others need controlled temperature and others can travel at ambient conditions, and these differences affect which providers can supply a given category.
Regulatory classification matters as well. Orphan and rare disease designations, advanced therapy classifications and biologic status each carry their own rules for import, manufacturing authorisation and safety monitoring, which lengthens or shortens the administrative path for different categories.
Product category and therapeutic area are therefore best read together. A cell therapy for a rare pediatric condition, for example, combines the handling needs of one category with the patient population of another, and the access route reflects both.
This page describes market structure only. It does not assess the effectiveness or safety of any medicine in any therapeutic area and it provides no clinical, prescribing or patient-eligibility guidance.
Oncology Medicines and Rare Disease Therapies
Oncology medicines are a major product category in access programs. New cancer therapies are frequently authorised in one country or region well before others, and treatment centres in the remaining markets often request product through named patient or early access routes during the gap.
The oncology pipeline is large and moves quickly, so a significant number of products are at any time in a position where they have shown enough promise to be filed for authorisation but are not yet available everywhere. That position is what creates demand for supply outside the normal channels.
Oncology programs are typically administered through cancer centres, university hospitals and specialist oncology pharmacies. The decision makers are medical oncologists and hospital pharmacy teams who deal with regulatory documentation as part of normal practice.
Rare disease therapies form a second large category. Because the patient population for each condition is small, the commercial case for launching in every country is limited, and manufacturers frequently sequence launches over several years, leaving long gaps in availability.
The route taken depends on the access program types and regulatory frameworks available in each country, with named patient requests common for very small populations and managed access programs used where a manufacturer wants consistent supply across several countries.
Rare disease access often depends on a small group of specialist centres. A single centre may serve patients from a wide area, and its pharmacy and clinical teams may hold more experience of requesting unlicensed products than a general hospital would.
Both categories are shaped by regulatory incentives for development. Orphan designation schemes and expedited review pathways bring products to filing sooner, and that pushes forward the point at which access programs become relevant.
Patient and physician organisations also play a part. Advocacy groups for rare conditions frequently raise awareness of access routes and ask manufacturers to establish programs, which can influence a sponsor's decision to supply a country before launch.
From a market perspective, oncology contributes breadth of demand across many centres, while rare disease contributes depth, with relatively few patients per product but long supply relationships and high administrative intensity.
Immunology, Neurology and Hematology Products
Immunology products, neurology therapies and hematology products form a middle group of categories in which access program activity is substantial but less concentrated than in oncology or rare disease.
Immunology covers biologics and specialty medicines for immune-mediated conditions. Many are authorised in several countries but launched on different schedules, and supply through access routes tends to fill short gaps between authorisation in one market and reimbursement in another.
Neurology therapies include products for conditions affecting the nervous system, some of which are rare. Access programs in this field are often linked to a small number of specialised centres and to products that are new to a given market.
Hematology products span treatments for blood disorders, including inherited conditions with small patient populations. Like rare disease therapies, they are often supplied to specialist treatment centres that coordinate care across a wide region.
The administrative pattern in these categories is mixed. Some programs are run by the manufacturer through a global managed access program, while others rely on named patient requests from hospitals that already know the product from abroad.
Supply conditions vary. Many immunology and hematology products are biologics that require controlled temperature handling, and neurology products include both oral medicines and infused or injected therapies with different logistics demands.
Reimbursement is a recurring theme. In these categories a product is often authorised but not yet funded, and access programs provide a bridge until a payer decision is made, which can last for months or longer.
Because the products are often already authorised in other regions, safety experience from outside the country may be available to the physician and regulator, and that information is typically considered during the approval of an individual request.
These categories are tracked separately in the report because their buyer base, handling needs and timing of demand differ from those of oncology and rare disease, even where the access routes used are similar.
|
SEGMENT INSIGHT Demand in these categories is driven more by the gap between authorisation and reimbursement than by the absence of any authorised product, so access program activity tracks payer decisions as closely as it tracks regulatory ones. |
Cell and Gene Therapies, Advanced Therapy Medicinal Products and Specialty Biologics
Cell and gene therapies, advanced therapy medicinal products (ATMPs) and specialty biologics are the most technically demanding categories to supply, and they are central to current access program discussion.
Advanced therapy medicinal products are a regulatory class that covers gene therapy, somatic cell therapy and tissue-engineered products. Cell and gene therapies are the largest part of this class, and the two terms are tracked as separate categories in the report because they overlap but are not identical.
These products are often manufactured for an individual patient or in small batches, and some must be shipped frozen or processed within a short time. Logistics, chain of identity and chain of custody requirements are therefore central to any program.
The pipeline is expanding quickly, and many products reach regulatory filing in only one or two regions. Patients elsewhere cannot obtain them through ordinary channels, and access programs are the main route available.
The supply route also depends on the drug development stage and manufacturer types involved, since a small developer at the filing stage faces very different constraints from a large company supplying a product that is already authorised elsewhere.
Treatment for these products is usually delivered at a limited number of qualified centres, which have the facilities and training to handle them. Access programs therefore involve centre qualification, an additional step that is not needed for conventional medicines.
Specialty biologics sit at the less demanding end of this group. They are complex protein-based medicines that need controlled-temperature handling but are produced in larger batches and shipped through established specialty distribution.
Regulatory requirements for ATMPs are demanding. Manufacturing authorisation, traceability and long-term follow-up obligations apply, and import of an unauthorised advanced therapy needs documentation that goes beyond what a conventional product requires.
As a result, program administration for these categories is intensive and costly, and it is a major driver of demand for specialist providers that combine regulatory, logistics and pharmacovigilance capability.
Metabolic Disorders, Infectious Diseases and Pediatric Rare Diseases
Three therapeutic areas complete the picture: metabolic disorders, infectious diseases and pediatric rare diseases. Each has a distinct pattern of demand for unlicensed supply.
Metabolic disorders include many inherited conditions that are individually rare. Products for these conditions are often launched in a few markets first, and the small patient numbers in each country make named patient supply a common route.
Infectious diseases produce a different pattern, driven by resistance, regional outbreaks and the withdrawal of older products. Demand here is often urgent and may be met through emergency import or special authorisation rather than a planned program.
Pediatric rare diseases combine small populations with additional regulatory and consent requirements for minors. Programs in this area are often coordinated through children's hospitals and specialist networks that cover large geographic areas.
In metabolic and pediatric rare disease areas, continuity matters. A patient who begins on a medicine supplied through an access program may need uninterrupted supply for years, which places weight on supply reliability and on the sponsor's commitment to continue the program.
Infectious disease programs are typically more variable. They may open quickly in response to a shortage or outbreak and close when the situation changes, so providers need to be able to respond at short notice.
Regulators and public health bodies are often directly involved in infectious disease supply, and government healthcare systems are frequent buyers, which differs from the hospital-led model that is typical of oncology and rare disease.
Across all three areas, the structure of demand is shaped by small numbers and by the importance of reliable, uninterrupted supply, and both factors favour providers with strong regulatory knowledge and dependable logistics.
Frequently Asked Questions
Oncology medicines and rare disease therapies are prominent categories, alongside immunology, neurology and hematology products. Cell and gene therapies, advanced therapy medicinal products and specialty biologics are the most demanding to supply.
ATMPs are a regulatory class of medicines that includes gene therapy, somatic cell therapy and tissue-engineered products. They are subject to specific manufacturing, traceability and follow-up rules, which make import and supply through access programs more complex than for conventional medicines.
New cancer therapies are often authorised in one country or region well before others, and the oncology pipeline is large and fast moving. Cancer centres in markets still awaiting authorisation or reimbursement therefore request product through access routes during the gap.
Yes, cell and gene therapies are supplied through access programs, usually to a limited number of qualified treatment centres. Programs involve centre qualification, specialised logistics and chain of identity requirements that go beyond those of conventional medicines.
Therapeutic area determines the patient population, the type of centre involved and the timing of demand, all of which shape which access route is used. A product category alone does not show how many patients are involved or where they are treated.